Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Phase 2
Not yet recruiting
- Conditions
- Glomerulonephritis
- Interventions
- Drug: KP104
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 52
- Registration Number
- NCT05517980
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
Phase 2
Not yet recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: KP104
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 24
- Registration Number
- NCT05504187
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104
Phase 1
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: KP104Drug: Placebo
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 80
- Registration Number
- NCT05490017
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104
Phase 2
Active, not recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: KP104
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Kira Pharmacenticals (US), LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT05476887
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, China
🇨🇳Chinese Academy of Medical Sciences Peking Union Medical College - Institute of Hematology Blood Diseases Hospital, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath